Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- HIV Groups Pin Hopes on MHLW’s Development Requests for Preventive Therapy
September 4, 2023
- Only 1.2% of NSCLC Patients Receiving Gene Panel Tests: Survey
September 1, 2023
- Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
August 31, 2023
- JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
August 29, 2023
- As 2040 Doctor Shortage Looms, Japan Consumer Healthcare Group Pushes Rx-to-OTC Switches for Hypertension Meds
August 25, 2023
- Japan Citizens’ Group Objects to HPV Vaccination in Males
August 25, 2023
- JPMA Taskforce Issues Proposal on Information Supply, Drug Development for Rare Diseases
August 18, 2023
- Economic Burden of Preventable Cancer “Over 1 Trillion Yen”: NCC, NCGM
August 17, 2023
- INES Proposes Extension of Public Funding for COVID Drugs
August 7, 2023
- IRA Could Create New Type of Drug Loss, Affecting Japan Too: PhRMA Official
July 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- JPA to Issue Policy Proposal to Address Lingering Supply Crisis
July 24, 2023
- More People Seek Self-Medication Tax Break in 2022
July 24, 2023
- JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
July 21, 2023
- Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
July 21, 2023
- Policy Veterans’ Group Lauds Expert Panel’s Report as “Epoch Making”
July 20, 2023
- Drug Reps in Japan Decline for 9th Consecutive Year, Falling Below 50,000: FY2022 Report
July 19, 2023
- Reform Regenerative Medicine Systems to Fight Lag, Loss: FIRM to Japan Govt
July 12, 2023
- Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
- PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
July 4, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…